血栓性血小板減少性紫斑(Thrombotic Thrombocytopenic Purpura)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Thrombotic Thrombocytopenic Purpura Overview 6
Therapeutics Development 7
Pipeline Products for Thrombotic Thrombocytopenic Purpura – Overview 7
Pipeline Products for Thrombotic Thrombocytopenic Purpura – Comparative Analysis 8
Thrombotic Thrombocytopenic Purpura – Therapeutics under Development by Companies 9
Thrombotic Thrombocytopenic Purpura – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Thrombotic Thrombocytopenic Purpura – Products under Development by Companies 13
Thrombotic Thrombocytopenic Purpura – Companies Involved in Therapeutics Development 14
Ablynx NV 14
Archemix Corp. 15
Glenmark Pharmaceuticals Ltd. 16
Kaketsuken K.K. 17
Octapharma AG 18
Omeros Corporation 19
Thrombotic Thrombocytopenic Purpura – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
ARC-15105 – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
BAX-930 – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
caplacizumab – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GBR-600 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
OMS-721 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
plasma (human) – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Thrombotic Thrombocytopenic Purpura – Recent Pipeline Updates 37
Thrombotic Thrombocytopenic Purpura – Dormant Projects 42
Thrombotic Thrombocytopenic Purpura – Product Development Milestones 43
Featured News & Press Releases 43
Feb 19, 2015: Omeros Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use 43
Dec 08, 2014: Additional Clinical Data From The Phase II Study With Ablynx’S Anti-Vwf Nanobody, Caplacizumab, Presented At The American Society Of Hematology Annual Meeting 44
Nov 26, 2014: Ablynx Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti Vwf nanobody, Caplacizumab 45
Jun 17, 2014: Ablynx’s Anti-vWF Nanobody, Caplacizumab, achieves Clinical Proof-of-concept in Phase II Titan Study 46
Apr 03, 2014: Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies 47
Jul 28, 2011: Initial Observations Of ABLYNX’S PHASE II TTP Program Presented At ISTH Congress 48
Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For ALX-0081 49
Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For Thrombotic Thrombocytopenic Purpura 50
Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For Thrombotic Thrombocytopenic Purpura 50
Aug 27, 2010: Octapharma Successfully Completes Uniplas Clinical Development 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53